VNRX
VolitionRx Limited [VNRX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
VNRX Stock Summary
Top 10 Correlated ETFs
VNRX
Top 10 Correlated Stocks
VNRX
In the News
VNRX Financial details
Company Rating
-
Market Cap
56.22M
Income
-35.32M
Revenue
775.3K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
110
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-1.96
Forward P/E
-
PEG
2.7
P/S
102.72
P/B
-32.53
P/C
-
P/FCF
-2.15
Quick Ratio
0.61
Current Ratio
0.69
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.51
EPS next Y
-
EPS next Q
-
EPS this Y
-9.09%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
4.05%
Revenue last 5Y
114.44%
Revenue Q/Q
47.67%
EPS Q/Q
-
-
-
-
-
SMA20
16.33%
SMA50
5.56%
SMA100
-9.52%
Inst Own
-
Inst Trans
-
ROA
-188%
ROE
12205%
ROC
-91.17%
Gross Margin
100%
Oper. Margin
-5416%
Profit Margin
-5201%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.55-2.1
52W High
-
52W Low
-
RSI
72.35
Rel Volume
6.31
Avg Volume
111.34K
Volume
702.85K
Perf Week
11.46%
Perf Month
30.41%
Perf Quarter
4.93%
Perf Half Y
-2.34%
-
-
-
-
Beta
1.346
-
-
Volatility
0.03%, 0.05%
Prev Close
6.67%
Price
0.63576
Change
9.61%
Company Profile
- Volume Average 111.34K
- Market Capitalization 56.22M
- Employee 110
- CEO Mr. Cameron Reynolds MBA
- Headquarters Austin,TX,US
- IPO Date 2012-03-02
-
Website
https://www.volition.com 
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
